Drug Trial Radar · NCT07176702
A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy
Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Mar 5, 2027
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pancreatic cancer is an extremely high-mortality malignancy. The chemotherapy regimen of gemcitabine combined with nab-paclitaxel (GEM-NABP) serves as one of the first-line standard therapies for metastatic pancreatic cancer. Given that traditional dual HER2 blockade (pertuzumab + trastuzumab) has demonstrated preliminary efficacy in HER2-expressing solid tumors, the novel clinical strategy of dual HER2 blockade (HLX22 + trastuzumab) combined with GEM-NAP offers the potential to improve outcomes for patients with HER2-positive pancreatic cancer.
Conditions
- Metastatic PDAC
- HER2-positive Status
Interventions
HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and ChemotherapyDrug
Drugs: HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV). Administration: Administered every 3 weeks until disease progression, unacceptable toxicity, or withdrawal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by investigators per RECIST v1.1.Time frame: up to 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital
Nanjing, Nanjing, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.